SciSparc Ltd. Announces Publication of U.S. Patent Application for Binge Behavior Disorders

SciSparc Ltd. (Nasdaq: SPRC) announced the publication of a U.S. patent application resulting from its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND). The patent application focuses on a combination therapy of MEAI (5-methoxy-2-aminoindane) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), targeting binge behavior disorders. These disorders include excessive alcohol consumption, eating disorders, tobacco use, compulsive shopping, and problematic sexual conduct. The therapy leverages MEAI’s psychedelic properties to reduce impulsivity and reward-seeking, enhanced by PEA’s anti-inflammatory and neuroprotective effects. Preclinical data supports the therapy’s potential efficacy in mitigating binge episodes while preserving natural reward pathways. This collaboration aims to address substance use and behavioral addictions without the risks associated with traditional interventions.